Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Zhaopeng Shi"'
Autor:
Chun Fu, Xuanye Wen, Zhaopeng Shi, Lin Rui, Na Jiang, Gelin Zhao, Rulin Wang, Jinpeng Zhao, YaoJun Yang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Ceracris kiangsu Tsai (C. kiangs) is a kind of forest pest, which can harm nearly 100 kinds of weeds and crops. In this study, based on 314 species distribution points of C. kiangsu which were obtained from Chinese herbaria, literatures and
Externí odkaz:
https://doaj.org/article/b08297fa80844bf4849ac395b3d17a27
Autor:
Shuyang Dai, Yaoyao Gu, Yong Zhan, Jie Zhang, Lulu Xie, Yi Li, Yifei Lu, Ran Yang, Enqing Zhou, Deqian Chen, Songbin Liu, Shan Zheng, Zhaopeng Shi, Kuiran Dong, Rui Dong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Aidi injection, a classic traditional Chinese medicine (TCM) formula, has been used on a broader scale in treating a variety of cancers. In this study, we aimed to explore the potential anti-tumor effects of Aidi injection in the treatmen
Externí odkaz:
https://doaj.org/article/15a494296fd14967b5c069ff8b4a0a3d
Autor:
Junyu Lin, Guanghua Chen, Mucan Jin, Zhaopeng Shi, Fulin Deng, Wenxian Zhang, Goulven Quéméner, Tao Shi, Su Yi, Dajun Wang
Publikováno v:
Physical Review X, Vol 13, Iss 3, p 031032 (2023)
Recent years have witnessed tremendous progress in creating and manipulating ground-state ultracold polar molecules. However, the two-body loss regardless of the chemical reactivities is still a hurdle for many future explorations. Here, we investiga
Externí odkaz:
https://doaj.org/article/2191aeb0f46e44ee87776c7edeb25362
Autor:
Zhaopeng Shi, Guifang Gan, Xiang Xu, Jieying Zhang, Yuan Yuan, Bo Bi, Xianfu Gao, Pengfei Xu, Wenbin Zeng, Jixi Li, Youqiong Ye, Aiwu Zhou, Naixia Zhang, Wen Liu, Shuhai Lin, Jun Mi
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid (3-HAA) is lower in tumor cells,
Externí odkaz:
https://doaj.org/article/3d499d84ce3e48009a0009c6b1acc40d
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Sorafenib is the FDA-approved first-line target drug for HCC patients. However, sorafenib only confers 3–5 months of survival benefit with
Externí odkaz:
https://doaj.org/article/cc968e95650444f7bcdc4f2dda2f7ecf
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 2, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/71e3415f337c491783df92f0e0a677b2
Autor:
Qing Wei, Hongliang Liu, Zhiying Ai, Yongyan Wu, Yingxiang Liu, Zhaopeng Shi, Xuexue Ren, Zekun Guo
Publikováno v:
Cellular Physiology and Biochemistry, Vol 44, Iss 5, Pp 2057-2072 (2017)
Background/Aims: Self-renewal is one of the most important features of embryonic stem (ES) cells. SC1 is a small molecule modulator that effectively maintains the self-renewal of mouse ES cells in the absence of leukemia inhibitory factor (LIF), seru
Externí odkaz:
https://doaj.org/article/de65e51be15f43fbaa178e4895238c42
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159700 (2016)
This study was performed to investigate the effects of genetically modified (GM) milk containing human beta-defensin-3 (HBD3) on mice by a 90-day feeding study. The examined parameters included the digestibility of GM milk, general physical examinati
Externí odkaz:
https://doaj.org/article/37ae13f99830402e9668400daf11a1c0
Autor:
Songshu Meng, Biao Li, Weiren Liu, Chengfang Shangguan, Jieying Zhang, Yuan Yuan, Jun Mi, Wujun Xiong, Zhaopeng Shi, Lei Chen, Guifang Gan
Publikováno v:
Theranostics
Objectives: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than 30% of HCC patients sensitive to sorafenib therapy. Thus, it's necessary to develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae21ad4874728030fee63f99d97cfa3a
http://europepmc.org/articles/PMC8058709
http://europepmc.org/articles/PMC8058709